Disease Site Groups (DSG)
The UCLA Health Jonsson Comprehensive Cancer Center operates a series of multi-disciplinary Disease Site Groups (DSGs) responsible for initial review of all interventional cancer clinical research protocols at UCLA. Each DSG is responsible for first stage scientific review, feasibility assessment and prioritization of new interventional clinical protocols as they relate to the patient populations and research focus of each Disease Site Group. The DSG considers relevant clinical programs, programmatic goals, expertise, and research interests in assessing both concepts and protocols.
The fifteen (15) Disease Site Groups at UCLA review the breadth of cancer-related disease areas, and include unique/specialized groups such as the Supportive Care DSG and Early Phase Clinical Research DSG. A full list of all Disease Site Groups is located below.
Formal DSG review and approval is required prior to Internal Scientific Peer Review Committee (ISPRC) submission for initial review of interventional clinical studies.
All studies reviewed by a Disease Site Group will be subject to:
- First stage review: approves trials to proceed to ISPRC review
- Prioritizes trials for respective histologies and areas, and evaluate feasibility
- Identifying competing protocols
- Setting and justifying the accrual goals for each protocol
Submitting your protocol for review by a DSG
- Secure the protocol. If a CDA is required to receive the protocol, contact the appropriate UCLA contract office to execute that agreement (Clinical Trial Contracts, TDG, OCGA).
- Submit the DSG Review Intake and Scoring Form for a new protocol.
- Once submitted, the new protocol will be placed on the agenda for the next DSG meeting. The PI and regulatory support named in the intake form will receive an email with potential review dates and DSG meeting login information. All meetings currently facilitated via Zoom.
Meetings, FAQs and Guidance
Disease Site Group Leads and Administrators
Administrators for all Disease Site Groups
The DSG Program Manager and Director are available to answer any questions about DSG review requirements, meeting schedule and decision outcome. The DSG PM is the primary point of contact.
DSG Program Manager
Marsha Noeline
310-810-4956
Chat with Marsha on Teams
[email protected]
DSG Program Director
Maggie Lindenbaum
424-440-0438
Chat with Maggie on Teams
[email protected]
Breast Oncology
Lead: Aditya Bardia, MD, MPH, [email protected]
Meetings: held bi-weekly every other Wednesday
Central Nervous System (CNS)
Co-Lead: Tim Cloughesy, MD, [email protected]
Co-Lead: Linda Liau, MD, PhD, [email protected]
Meetings: held every other Thursday
Early Phase Clinical Research
Tumor-specific Phase I studies may be reviewed by a tumor-specific DSG, unless the study is for multiple tumor types (≥3), then it must be reviewed by the Early Phase Clinical Research DSG.
Lead: Lee Rosen, MD, [email protected]
Meetings: held bi-weekly every other Monday
Gastrointestinal-Pancreas Oncology
Co-Lead: Joel Randolph (Randy) Hecht, MD, [email protected]
Co-Lead: Timothy Donahue, MD, [email protected]
Meetings: held bi-weekly every other Friday
Genitourinary Oncology
Co-Lead: Allan Pantuck, MD, [email protected]
Co-Lead: Alexandra Drakaki, MD, PhD, [email protected]
Meetings: held bi-weekly every other Friday
Gynecologic Oncology
Co-Lead: Ritu Salani, MD, [email protected]
Co-Lead: Gottfried Konecny, MD, [email protected]
Meetings: held weekly every Friday
Head and Neck Oncology
Co-Lead: Deborah Wong, MD, PhD, [email protected]
Co-Lead: Amar Kishan, MD, PhD, [email protected]
Meetings: held bi-weekly every other Wednesday
Hematologic Malignancies
Lead: Gary Schiller, MD, [email protected]
Meetings: held bi-weekly every other Friday
Hepatobiliary Oncology
Co-Lead: Vatche Agopian, MD, [email protected]
Co-Lead: Richard Finn, MD, [email protected]
Meetings: held every other Monday
Lymphoma
Co-Lead: Sven de Vos, MD, PhD, [email protected]
Co-Lead: Herbert Eradat, MD, [email protected]
Meetings: held every Thursday
Melanoma
Co-Lead: Bartosz Chmielowski, MD, PhD, [email protected]
Co-Lead: Joseph Crompton, MD, [email protected]
Meetings: held bi-weekly every other Thursday
Pediatric Oncology
Lead: Noah Federman, MD, [email protected]
Meetings: held every other Monday
Sarcoma
Co-Lead: Arun Singh, MD, [email protected]
Co-Lead: Frederick Eilber, MD, [email protected]
Meetings: held every other Thursday
Supportive Care
If the protocol attempts to alleviate a symptom of cancer as opposed to the cancer itself, use this DSG.
Lead: John Glaspy, MD, [email protected]
Meetings: held bi-weekly every other Tuesday
Thoracic Cancer
Co-Lead: Eddie Garon, MD, [email protected]
Co-Lead: Jonathan Goldman, MD, [email protected]
Meetings: held bi-weekly every other Monday